β-Amyloid-acetylcholine molecular interaction: new role of cholinergic mediators in anti-Alzheimer therapy?

References

• 1 Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2(8000), 1403 (1976).
  Medline CASGoogle Scholar
• 2 Hardy JA, Higgins GA. Alzheimer's disease: the amyloid cascade hypothesis. Science 256(5054), 184–185 (1992).
  Medline CASGoogle Scholar
• 3 Baglioni S, Casamenti F, Bucciantini M et al. Prefibrillar amyloid aggregates could be generic toxins in higher organisms. J. Neurosci. 26(31), 8160–8167 (2006).
  Medline CASGoogle Scholar
• 4 Lue LF, Kuo YM, Roher AE et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. 155(3), 853–862 (1999).
  Medline CASGoogle Scholar
• 5 Mclean CA, Cherny RA, Fraser FW et al. Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Annu. Rev. Neurosci. 46(6), 860–866 (1999).
  CASGoogle Scholar
• 6 Kayed R, Pensalfini A, Margol L et al. Annular protofibrils are a structurally and functionally distinct type of amyloid oligomer. J. Biol. Chem. 284(7), 4230–4237 (2009).
  Medline CASGoogle Scholar
• 7 Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch. Neurol. 42(11), 1097–1105 (1985).
  Medline CASGoogle Scholar
• 8 Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol. 8(2), 101–112 (2007).
  Medline CASGoogle Scholar
• 9 Picone P, Carrotta R, Montana G, Nobile MR, San Biagio PL, Di Carlo M. Abeta oligomers and fibrillar aggregates induce different apoptotic pathways in LAN5 neuroblastoma cell cultures. Biophys. J. 96(10), 4200–4211 (2009).
  Medline CASGoogle Scholar
• 10 Stains CI, Mondal K, Ghosh I. Molecules that target beta-amyloid. ChemMedChem 2(12), 1674–1692 (2007).
  Medline CASGoogle Scholar
• 11 Hamley IW. The amyloid beta peptide: a chemist's perspective. Role in Alzheimer's and fibrillization. Chem. Rev. 112(10), 5147–5192 (2012).
  Medline CASGoogle Scholar
• 12 Nasica-Labouze J, Nguyen PH, Sterpone F et al. Amyloid beta protein and Alzheimer's disease: when computer simulations complement experimental studies. Chem. Rev. 115(9), 3518–3563 (2015).
  Medline CASGoogle Scholar
• 13 Campiglia P, Esposito C, Scrima M et al. Conformational stability of A beta-(25–35) in the presence of thiazolidine derivatives. Chem. Biol. Drug Des. 69(2), 111–118 (2007).
  Medline CASGoogle Scholar
• 14 Campiglia P, Scrima M, Grimaldi M et al. A new series of 1,3-dihidro-imidazo 1,5-c thiazole-5,7-dione derivatives: synthesis and interaction with A beta(25–35) amyloid peptide. Chem. Biol. Drug Des. 74(3), 224–233 (2009).
  Medline CASGoogle Scholar
• 15 Vitiello G, Grimaldi M, D'Ursi AM, D'Errico G. The iA beta 5p beta-breaker peptide regulates the A beta(25–35) interaction with lipid bilayers through a cholesterol-mediated mechanism. Biochem. Biophys. Res. Commun. 417(1), 88–92 (2012).
  Medline CASGoogle Scholar
• 16 Saponetti MS, Grimaldi M, Scrima M et al. Aggregation of A beta(25–35) on DOPC and DOPC/DHA bilayers: an atomic force microscopy study. PLoS ONE 9(12), (2014).
  Google Scholar
• 17 Esposito C, Tedeschi A, Scrima M et al. Exploring interaction of beta-amyloid segment (25–35) with membrane models through paramagnetic probes. J. Pept. Sci. 12(12), 766–774 (2006).
  Medline CASGoogle Scholar
• 18 Pike CJ, Walencewicz-Wasserman AJ, Kosmoski J, Cribbs DH, Glabe CG, Cotman CW. Structure–activity analyses of beta-amyloid peptides: contributions of the beta 25–35 region to aggregation and neurotoxicity. J. Neurochem. 64(1), 253–265 (1995).
  Medline CASGoogle Scholar
• 19 Pike CJ, Burdick D, Walencewicz AJ, Glabe CG, Cotman CW. Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state. J. Neurosci. 13(4), 1676–1687 (1993).
  Medline CASGoogle Scholar
• 20 Terzi E, Hoelzemann G, Seelig J. Alzheimer beta-amyloid peptide 25–35: electrostatic interactions with phospholipid membranes. Biochemistry 33(23), 7434–7441 (1994).
  Medline CASGoogle Scholar
• 21 Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp. Neurol. 163(2), 495–529 (2000).
  Medline CASGoogle Scholar
• 22 Craig LA, Hong NS, Mcdonald RJ. Revisiting the cholinergic in the development of Alzheimer's disease. Neurosci. Biobehav. Rev. 35(6), 1397–1409 (2011).
  Medline CASGoogle Scholar
• 23 Prasansuklab A, Tencomnao T. Amyloidosis in Alzheimer's disease: the toxicity of amyloid Beta (A beta), mechanisms of its accumulation and implications of medicinal plants for therapy. Evid. Based Complement. Alternat. Med. 2013, 413808 (2013).
  MedlineGoogle Scholar
• 24 Pedersen WA, Kloczewiak MA, Blusztajn JK. Amyloid beta-protein reduces acetylcholine synthesis in a cell line derived from cholinergic neurons of the basal forebrain. Proc. Natl Acad. Sci. USA 93(15), 8068–8071 (1996).
  Medline CASGoogle Scholar
• 25 Kar S, Seto D, Gaudreau P, Quirion R. Beta-amyloid-related peptides inhibit potassium-evoked acetylcholine release from rat hippocampal slices. J. Neurosci. 16(3), 1034–1040 (1996).
  Medline CASGoogle Scholar
• 26 Vaucher E, Aumont N, Pearson D, Rowe W, Poirier J, Kar S. Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats. J. Chem. Neuroanat. 21(4), 323–329 (2001).
  Medline CASGoogle Scholar
• 27 Ehrenstein G, Galdzicki Z, Lange GD. The choline-leakage hypothesis for the loss of acetylcholine in Alzheimer's disease. Biophys. J. 73(3), 1276–1280 (1997).
  Medline CASGoogle Scholar
• 28 Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258(5080), 304–307 (1992).
  Medline CASGoogle Scholar
• 29 Lin L, Georgievska B, Mattsson A, Isacson O. Cognitive changes and modified processing of amyloid precursor protein in the cortical and hippocampal system after cholinergic synapse loss and muscarinic receptor activation. Proc. Natl Acad. Sci. USA 96(21), 12108–12113 (1999).
  Medline CASGoogle Scholar
• 30 Aztiria E, Cataudella T, Spampinato S, Leanza G. Septal grafts restore cognitive abilities and amyloid precursor protein metabolism. Neurobiol. Aging 30(10), 1614–1625 (2009).
  Medline CASGoogle Scholar
• 31 Antonini V, Marrazzo A, Kleiner G et al. Anti-amnesic and neuroprotective actions of the sigma-1 receptor agonist (-)-MR22 in rats with selective cholinergic lesion and amyloid infusion. J. Alzheimer's Dis. 24(3), 569–586 (2011).
  Medline CASGoogle Scholar
• 32 Sorrentino P, Iuliano A, Polverino A, Jacini F, Sorrentino G. The dark sides of amyloid in Alzheimer's disease pathogenesis. FEBS Lett. 588(5), 641–652 (2014).
  Medline CASGoogle Scholar
• 33 Wattmo C, Wallin AK, Minthon L. Functional response to cholinesterase inhibitor therapy in a naturalistic Alzheimer's disease cohort. BMC Neurol. 12, 134 (2012).
  Medline CASGoogle Scholar
• 34 Viayna E, Sabate R, Munoz-Torrero D. Dual inhibitors of beta-amyloid aggregation and acetylcholinesterase as multi-target anti-Alzheimer drug candidates. Curr. Top. Med. Chem. 13(15), 1820–1842 (2013).
  Medline CASGoogle Scholar
• 35 Shaik JB, Palaka BK, Penumala M et al. Synthesis, biological evaluation and molecular docking of 8-imino-2-oxo-2H,8H-pyrano[2,3-f]chromene analogues: new dual AChE inhibitors as potential drugs for the treatment of Alzheimers disease. Chem. Biol. Drug Des. 88(1), 43–53 (2016).
  Medline CASGoogle Scholar
• 36 Ambure P, Roy K. CADD modeling of multi-target drugs against Alzheimer's disease. Curr. Drug Targets (2015) (Epub ahead of print).
  MedlineGoogle Scholar
• 37 Dinamarca MC, Sagal JP, Quintanilla RA, Godoy JA, Arrazola MS, Inestrosa NC. Amyloid-beta-acetylcholinesterase complexes potentiate neurodegenerative changes induced by the Abeta peptide. Implications for the pathogenesis of Alzheimer's disease. Mol. Neurodegener. 5, 4 (2010).
  MedlineGoogle Scholar
• 38 Zagorski MG, Yang J, Shao H, Ma K, Zeng H, Hong A. Methodological and chemical factors affecting amyloid beta peptide amyloidogenicity. Methods Enzymol. 309, 189–204 (1999).
  Medline CASGoogle Scholar
• 39 Whitmore L, Wallace BA. DICHROWEB, an online server for protein secondary structure analyses from circular dichroism spectroscopic data. Nucleic Acids Res. 32, W668–W673 (2004).
  Medline CASGoogle Scholar
• 40 Kotler SA, Walsh P, Brender JR, Ramamoorthy A. Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease. Chem. Soc. Rev. 43(19), 6692–6700 (2014).
  Medline CASGoogle Scholar
• 41 Grimaldi M, Scrima M, Esposito C et al. Membrane charge dependent states of the beta-amyloid fragment Abeta (16–35) with differently charged micelle aggregates. Biochim. Biophys. Acta 1798(3), 660–671 (2010).
  Medline CASGoogle Scholar
• 42 D'Ursi AM, Armenante MR, Guerrini R, Salvadori S, Sorrentino G, Picone D. Solution structure of amyloid beta-peptide (25–35) in different media. J. Med. Chem. 47(17), 4231–4238 (2004).
  MedlineGoogle Scholar
• 43 Severini C, Passeri PP, Ciotti M et al. Bindarit, inhibitor of CCL2 synthesis, protects neurons against amyloid-beta-induced toxicity. J. Alzheimer's Dis. 38(2), 281–293 (2014).
  Medline CASGoogle Scholar
• 44 Pimplikar SW. Neuroinflammation in Alzheimer's disease: from pathogenesis to a therapeutic target. J. Clin. Immunol. 34, S64–S69 (2014).
  Medline CASGoogle Scholar
• 45 Rodríguez-Arellano JJ, Parpura V, Zorec R, Verkhratsky A. Astrocytes in physiological aging and Alzheimer's disease. Neuroscience 323, 170–182 (2015).
  MedlineGoogle Scholar
• 46 Nagele RG, D'andrea MR, Lee H, Venkataraman V, Wang HY. Astrocytes accumulate A beta 42 and give rise to astrocytic amyloid plaques in Alzheimer disease brains. Brain Res. 971(2), 197–209 (2003).
  Medline CASGoogle Scholar
• 47 Tarkowski E, Liljeroth A-M, Minthon L, Tarkowski A, Wallin A, Blennow K. Cerebral pattern of pro-and anti-inflammatory cytokines in dementias. Brain Res. Bull. 61(3), 255–260 (2003).
  Medline CASGoogle Scholar
• 48 Singh I, Sorrentino G, Sitar D, Kanfer J. Indomethacin and nordihydroguaiaretic acid inhibition of amyloid β protein (25–35) activation of phospholipases A 2 and D of LA-N-2 cells. Neurosci. Lett. 222(1), 5–8 (1997).
  Medline CASGoogle Scholar
• 49 Desbène C, Malaplate-Armand C, Youssef I et al. Critical role of cPLA 2 in A β oligomer-induced neurodegeneration and memory deficit. Neurobiol. Aging 33(6), 1123.e1117–1123.e1129 (2012).
  Google Scholar
• 50 Wood SJ, Mackenzie L, Maleeff B, Hurle MR, Wetzel R. Selective inhibition of Abeta fibril formation. J. Biol. Chem. 271(8), 4086–4092 (1996).
  Medline CASGoogle Scholar
• 51 Ryan TM, Friedhuber A, Lind M, Howlett GJ, Masters C, Roberts BR. Small amphipathic molecules modulate secondary structure and amyloid fibril-forming kinetics of Alzheimer disease peptide Abeta(1–42). J. Biol. Chem. 287(20), 16947–16954 (2012).
  Medline CASGoogle Scholar
• 52 Vitiello G, Grimaldi M, Ramunno A et al. Interaction of a beta-sheet breaker peptide with lipid membranes. J. Pept. Sci. 16(2), 115–122 (2010).
  Medline CASGoogle Scholar
• 53 D'errico G, Vitiello G, Ortona O, Tedeschi A, Ramunno A, D'ursi AM. Interaction between Alzheimer's A beta(25–35) peptide and phospholipid bilayers: the role of cholesterol. Biochim. Biophys. Acta 1778(12), 2710–2716 (2008).
  MedlineGoogle Scholar
• 54 Jao SC, Ma K, Talafous J, Orlando R, Zagorski MG. Trifluoroacetic acid pretreatment reproducibly disaggregates the amyloid beta-peptide. J. Exp. Clin. Cancer Res. 4(4), 240–252 (1997).
  CASGoogle Scholar
• 55 Culmsee C, Gerling N, Lehmann M et al. Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TRKA and requires the common neurotrophin receptor p75. Neuroscience 115(4), 1089–1108 (2002).
  Medline CASGoogle Scholar
• 56 Volonte C, Ciotti MT, Battistini L. Development of a method for measuring cell number: application to CNS primary neuronal cultures. Cytometry 17(3), 274–276 (1994).
  Medline CASGoogle Scholar